Ensuring access to treatments for underserved populations is a key priority in both the European Medicines Agency’s strategy for regulatory science and the EU Commission’s pharmaceutical strategy. In the last decade, the repositioning of drugs has regularly been highlighted as a promising innovation strategy for drug development for rare diseases, and various political initiatives have been taken to support such development. However, it has been difficult to assess whether this strategy has been a success. Deficiencies in terminology and methods leave the extent and character of repositioning for orphan diseases opaque, impeding sound policymaking.
These and related topics will be discussed at a webinar organized by the Nordic Intellectual Property Law Review (Nordiskt Immateriellt Rättsskydd, NIR). Speaking at the webinar will be Jakob Wested, PhD, industrial postdoc, University of Copenhagen, and John Liddicoat, PhD, Senior Research Associate; Affiliated Lecturer, University of Cambridge, who recently published an article in NIR (issue 4/2021) on the topic of Patent Repositioning for rare diseases – too much, too little or just right? At the webinar, the speakers will present their method and analysis of the contemporary repositioning landscape for rare diseases and discuss some of the policy issues, such as overcompensation.
The presentation will be followed by comments, questions and a joint discussion.
Time and place: Monday 25 April from 11:45 to 12:45 CET. Registration is mandatory. Zoom link and invoice will be sent out after registration. (Students and doctoral candidates may participate for free).
Fee: 400 SEK, excl. VAT (if applicable)
Comments: Associate Professor Ana Nordberg, Faculty of Law, Lund University
Moderator: Linnea Harnesk, Associate, Westerberg & Partners
